Complete list of major GLP-1 medications available in the US.
The first GLP-1 receptor agonist, exenatide (Byetta), was approved by the FDA in 2005 for type 2 diabetes. It was derived from the venom of the Gila monster lizard and marked a breakthrough in diabetes treatment. For nearly a decade, GLP-1 drugs remained a niche diabetes therapy, requiring daily injections and producing modest weight loss as a side effect. In 2014, liraglutide (Saxenda) became the first GLP-1 approved specifically for weight management, though results were underwhelming by today's standards. The landscape transformed in 2017 when semaglutide (Ozempic) arrived for diabetes, and then again in 2021 when Wegovy—a higher-dose version of the same drug—was approved for weight loss. The game shifted fundamentally in 2022 with tirzepatide (Mounjaro) for diabetes and 2023 with Zepbound for weight loss. Tirzepatide's dual mechanism of action and dramatically superior weight loss results have made it the current gold standard. Today, GLP-1 and dual GLP-1/GIP drugs are among the most potent weight loss medications ever developed, moving from niche diabetes treatment to mainstream weight management.
These newer GLP-1s represent the current standard of care for weight management and diabetes. They're designed for both efficacy and convenience, and they work through one of two mechanisms.
Manufacturer: Novo Nordisk
Indication: Chronic weight management
FDA Approved: November 2021
Mechanism: Single GLP-1 receptor agonist
Administration: Once-weekly subcutaneous injection (prefilled pen)
Dose Range: 0.25mg to 2.4mg weekly (maintenance dose is 2.4mg)
Average Weight Loss: 15% of body weight over 68 weeks in clinical trials. Some patients achieve up to 22% loss.
What You Should Know: Wegovy is the dedicated weight-loss formulation of semaglutide, developed specifically for weight management (unlike Ozempic, which is for diabetes). It's self-injected once per week, typically on the same day. Dosing starts low and gradually increases over 16 weeks to minimize side effects. Most patients reach the target 2.4mg dose by month 4. Common side effects include nausea, which often improves with time. Many people find weekly injections convenient and report good adherence.
Manufacturer: Eli Lilly
Indication: Chronic weight management
FDA Approved: November 2023
Mechanism: Dual GLP-1/GIP receptor agonist
Administration: Once-weekly subcutaneous injection (prefilled pen)
Dose Range: 2.5mg to 15mg weekly (maintenance varies by response)
Average Weight Loss: 20–22% of body weight in clinical trials, significantly outperforming semaglutide. Some patients lose 25%+.
What You Should Know: Zepbound is the newest weight-loss GLP-1 and currently the most effective. It works on two receptors (GLP-1 and GIP) instead of one, which creates superior results for both weight loss and blood sugar control. Like Wegovy, it's injected once weekly, but the dose escalation schedule is different. It typically takes 20 weeks to reach the target maintenance dose (10–15mg), so patience is important. The dual mechanism explains why it outperforms semaglutide, and many people ask their doctors about it specifically for that reason.
Manufacturer: Novo Nordisk
Indication: Type 2 diabetes (approved); weight loss (frequent off-label use)
FDA Approved: December 2017 (for diabetes)
Mechanism: Single GLP-1 receptor agonist
Administration: Once-weekly subcutaneous injection (prefilled pen)
Dose Range: 0.25mg to 1mg weekly
Weight Loss Profile: Modest—typically 5–10% of body weight over 6 months at the approved 1mg diabetes dose. Clinicians sometimes prescribe higher doses off-label for weight loss, but this is not FDA-approved and may not be covered by insurance.
What You Should Know: Ozempic was developed for type 2 diabetes but became famous because patients noticed significant weight loss. Insurance coverage is usually tied to a diabetes diagnosis. If you have both diabetes and weight loss goals, it's a practical option, but if weight loss is your primary goal and you don't have diabetes, Wegovy is the officially approved choice and may have better insurance coverage. Many people transition from Ozempic to Wegovy when weight loss is their focus.
Manufacturer: Eli Lilly
Indication: Type 2 diabetes (approved); weight loss (increasingly off-label)
FDA Approved: May 2022 (for diabetes)
Mechanism: Dual GLP-1/GIP receptor agonist
Administration: Once-weekly subcutaneous injection (prefilled pen)
Dose Range: 2.5mg to 15mg weekly
Weight Loss Profile: Significant—the dual mechanism means it produces substantial weight loss even at diabetes doses. Average 15–20% weight loss is common, which is better than Ozempic for the same dose tier.
What You Should Know: Mounjaro is the diabetes version of tirzepatide, and it's increasingly prescribed off-label for weight loss due to its superior efficacy compared to semaglutide-based drugs. Insurance coverage is typically tied to a diabetes diagnosis, but the weight loss results are compelling, especially for patients who have both conditions. If you have type 2 diabetes and need weight loss, this is worth discussing with your doctor.
For patients who strongly prefer pills to injections, there is currently one FDA-approved oral GLP-1. It offers convenience but with a trade-off in effectiveness.
Manufacturer: Novo Nordisk
Indication: Type 2 diabetes
FDA Approved: September 2019
Mechanism: Single GLP-1 receptor agonist (oral form)
Administration: Once-daily oral tablet (must be taken on completely empty stomach, 30 minutes before food or drink)
Dose Range: 3mg, 7mg, or 14mg daily
Weight Loss Profile: Modest—typically 5–8% of body weight. Less effective than injectable semaglutide because the body absorbs less of the drug through the digestive system.
What You Should Know: Rybelsus is the convenience option, but the empty-stomach requirement is strict and inconvenient for many people—you can't eat, drink, or take other medications for 30 minutes after each dose. That alone makes it less practical than weekly injections. Most clinicians recommend it only for patients with a genuine aversion to needles. Weight loss results are disappointing compared to injections, which is why many patients try Rybelsus and later switch to Wegovy for better results.
These medications pioneered the GLP-1 class and remain in use today, though they're less convenient and less effective than newer options. Understanding them helps explain why newer drugs are preferred.
Manufacturer: Novo Nordisk
Indication: Type 2 diabetes
FDA Approved: January 2010
Mechanism: Single GLP-1 receptor agonist
Administration: Once-daily subcutaneous injection (prefilled pen)
Dose Range: 0.6mg to 1.8mg daily
Weight Loss Profile: Very modest—typically 2–4 lbs per month, roughly 5–7% over a year.
What You Should Know: Victoza has an excellent safety record—it's been used for over 14 years. It's reliable and well-tolerated, which made it the standard of care for decades. The drawback is that it requires daily injections (not weekly) and produces significantly less weight loss than modern drugs. Insurance often covers it better than newer options, and it's appropriate for patients with type 2 diabetes who have failed on other agents. But for weight loss specifically, it's been largely superseded by tirzepatide and semaglutide.
Manufacturer: Novo Nordisk
Indication: Chronic weight management
FDA Approved: December 2014
Mechanism: Single GLP-1 receptor agonist
Administration: Once-daily subcutaneous injection (prefilled pen)
Dose Range: 0.6mg to 3.0mg daily (maintenance is 3.0mg)
Weight Loss Profile: Modest—average 8–10% of body weight over one year in clinical trials.
What You Should Know: Saxenda was the first GLP-1 approved specifically for weight management, and it's still used today. However, it requires daily injections—not weekly—which is less convenient. Weight loss results are significantly lower than Wegovy or Zepbound. Its main advantage is a long track record and sometimes better insurance coverage due to its age. It's a reasonable option for patients who've been on it successfully for years, but new patients are typically started on Wegovy or Zepbound instead.
A few other GLP-1 agonists remain available and are sometimes prescribed, usually when first-line options aren't suitable or for patients already stable on them.
Manufacturer: Eli Lilly
Indication: Type 2 diabetes
FDA Approved: September 2014
Mechanism: Single GLP-1 receptor agonist
Administration: Once-weekly subcutaneous injection (prefilled pen)
Dose Range: 0.75mg to 1.5mg weekly
Weight Loss Profile: Modest—typically 4–6 lbs per month (5–8% annually).
Clinical Use: Trulicity is reliable for diabetes management and has been used for a decade. However, it's not approved for weight loss and produces less weight loss than newer semaglutide and tirzepatide drugs. It's an option for type 2 diabetes patients, but tirzepatide (Mounjaro) has largely replaced it as the preferred weekly GLP-1 for diabetes.
Manufacturer: AstraZeneca
Indication: Type 2 diabetes
FDA Approved: 2005 (Byetta, immediate-release); 2012 (Bydureon, extended-release)
Mechanism: GLP-1 receptor agonist (distinct mechanism from others)
Administration: Byetta: twice-daily injections | Bydureon: once-weekly injection
Dose Range: Byetta: 5mcg or 10mcg twice daily | Bydureon: 2mg weekly
Weight Loss Profile: Minimal—2–5 lbs typically.
Historical Context: Exenatide was the very first GLP-1 approved (2005) and a major breakthrough at the time. Today, it's rarely prescribed because newer drugs are more convenient (weekly dosing) and more effective. You might encounter exenatide if you have a specific allergy to other GLP-1s or if your insurance has restrictions, but it's otherwise considered obsolete by modern standards.
All FDA-approved GLP-1 drugs work by activating the GLP-1 receptor, but not all of them do only that. This distinction explains a lot about why tirzepatide-based drugs outperform semaglutide-based drugs.
Single GLP-1 Agonists: Semaglutide (Wegovy, Ozempic, Rybelsus) and liraglutide (Saxenda, Victoza) activate only the GLP-1 receptor. They're effective, but they hit one target.
Dual GLP-1/GIP Agonists: Tirzepatide (Zepbound, Mounjaro) activates both the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another hormone that regulates blood sugar and appetite. By hitting both receptors, tirzepatide produces a compounding effect: more appetite suppression, better blood sugar control, and more weight loss. This is why Zepbound's 20–22% average weight loss beats Wegovy's 15%.
In plain terms: dual agonists are more powerful because they work on two switches instead of one. As new drugs enter the market, expect more dual agonists, as they represent the future of the class.
Once-weekly injections (Wegovy, Ozempic, Mounjaro, Zepbound, Trulicity, Bydureon) are standard today and a major quality-of-life improvement. You pick a day each week—say, Sunday morning—and inject. For most patients, this is convenient and improves adherence.
Daily injections (Saxenda, Victoza, Byetta) are older and less convenient. You inject every morning or multiple times daily. This is why newer weekly options are preferred; daily dosing is a burden that affects compliance over time.
Oral dosing (Rybelsus) is once-daily, but the empty-stomach requirement is strict and impractical for many people.
Beyond FDA-approved drugs, compounded versions of semaglutide and tirzepatide are widely available through telehealth and concierge weight loss programs. These are manufactured in licensed compounding pharmacies—not by pharmaceutical companies—and typically cost less than brand-name drugs (often $200–$400 per month vs. $1,000+). However, there are important trade-offs:
If cost is a barrier to brand-name GLP-1s, compounded drugs can be an option, but choose your provider carefully. See our detailed guide on compounded GLP-1 medications for how to evaluate compounding pharmacies.
The GLP-1 pipeline is robust, with several promising candidates in late-stage trials. These could expand options significantly in the next 2–3 years.
Status: Phase 3 clinical trials (expected FDA decision 2024–2025)
Mechanism: Triple agonist—activates GLP-1, GIP, and glucagon receptors simultaneously
Early Results: Phase 2 data showed weight loss ranging from 16% to 22%, comparable to or better than tirzepatide depending on the dose. Some trial participants achieved 25%+ weight loss.
What to Expect: The triple mechanism (three targets instead of two) could be a significant jump forward. If approved, it might become the new gold standard for weight loss. It's administered as a once-weekly injection, similar to current GLP-1s.
Status: Late-stage clinical trials
Mechanism: Single GLP-1 agonist in pill form, specifically designed for weight management
Expected Timeline: Potential approval 2024–2025
What to Expect: An oral pill with improved bioavailability compared to Rybelsus (which is a current tablet but has low absorption). This is important because Rybelsus's weak results are partly due to poor absorption. A next-generation oral could deliver injection-like results in a pill, which would be a game-changer for patients who hate needles.
Status: Phase 2 clinical trials
Mechanism: First-in-class oral non-peptide GLP-1 receptor agonist (engineered differently from other GLP-1s)
What's Different: Traditional GLP-1 drugs are peptides (chains of amino acids) that must be injected because they're destroyed by stomach acid. Orforglipron is a small molecule engineered to survive the digestive tract and be absorbed as a pill. Early trials show it activates GLP-1 receptors effectively via oral dosing.
Expected Timeline: Potential approval 2025–2026 (if Phase 2/3 trials continue successfully)
Why It Matters: If it delivers injection-level weight loss in a daily pill, it could dramatically expand access and adherence. Millions of people avoid GLP-1s because of needle anxiety; an effective oral could change the game.
Status: Phase 2 clinical trials
Mechanism: Dual GLP-1/GCG agonist (GCG is glucagon)
What to Expect: Another dual agonist designed to compete with tirzepatide. Early data suggests comparable weight loss to tirzepatide, with once-weekly or twice-weekly dosing options.
To help you understand the hierarchy, here's what typical average weight loss looks like across the GLP-1 class:
These figures represent typical averages in published clinical trials. Individual results vary significantly—some people lose more, some less. Also, these are comparisons at approved therapeutic doses. Clinicians sometimes dose drugs off-label, which can change the outcomes.
Not sure which GLP-1 program is right?